- Yondelis® is an important treatment option for soft tissue sarcoma
- Commercialization to begin summer 2020
MONTREAL, June 8, 2020 /CNW Telbec/ - Valeo Pharma Inc. (CSE: VPH) ("Valeo" or the "Company"), a Canadian specialty pharmaceutical company, announced today that it has received a Notice of Compliance from Health Canada authorizing the transfer of the commercial rights of Yondelis® to Valeo. Yondelis® (trabectedin) is a novel marine-derived antitumor agent manufactured by PharmaMar S.A., based in Madrid, Spain.
"With the receipt of Health Canada's approval, Valeo can now assume the commercialization of Yondelis® in Canada. Yondelis® is an important treatment option for patients with soft tissue sarcoma and represents a key addition to our specialty product portfolio", said Steve Saviuk, Valeo's President and CEO. "Yondelis® is the first of five product approvals and launches that we anticipate over the second half of the year. We expect that these launches will be materially accretive to our revenues and profitability".
Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent. Yondelis is currently approved, in Canada, for the treatment of patients with metastatic liposarcoma or leiomyosarcoma after failure of prior anthracycline and ifosfamide chemotherapy. Yondelis is also approved, in combination with Caelyx, for second line treatment of patients with platinum-sensitive ovarian cancer.
About Valeo Pharma
Valeo Pharma is a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on LinkedIn and Twitter.
Forward Looking Statements
This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE Valeo Pharma inc.
For further information: Valeo Pharma: Steve Saviuk, President and CEO, 514 693-8830, [email protected]; Frederic Dumais, Director Communications and Investor Relations, 514-782-8803, [email protected]